@article{APM1585,
author = {Elzbieta Nowara and Joanna Huszno},
title = {Skin toxicity after palliative chemotherapy containing pegylated liposomal doxorubicin for ovarian cancer patients},
journal = {Annals of Palliative Medicine},
volume = {2},
number = {2},
year = {2013},
keywords = {},
abstract = {Background: Skin toxicity in the course of anticancer treatment occurs in majority of patients and may substantially reduce quality of life. Pegylated liposomal doxorubicin (PLD) is an anthracyclines' derivative with reducing severity of cardiotoxicity and myelosuppression but with localized skin lesions on the palms and the soles (PPE).
Material and methods: The retrospective analysis included medical records of ovarian cancer patients who were treated with PLD due to disease progression after prior therapy. The impact of several factors on the risk and severity of PPE was analyzed.
Results: In analyzed group of ovarian cancer PPE occurred more often in patients who have previously received more than two chemotherapy lines, P=0.09. The risk of PPE increased with the number of chemotherapy cycles, P},
issn = {2224-5839}, url = {https://apm.amegroups.org/article/view/1585}
}